Corrado M L, Grad C, Sabbaj J
Am J Med. 1987 Jun 26;82(6B):70-4. doi: 10.1016/0002-9343(87)90622-x.
A retrospective analysis of data from the treatment of 95 men with nonbacteremic urinary tract infections (UTIs) (clean-catch urinary bacterial count greater than or equal to 10(5) colony-forming units/ml) who received norfloxacin (400 mg orally twice daily) was performed. Treatment duration ranged from a required minimum of seven days to a maximum of 30 days. If an underlying anatomic or functional condition existed that might decrease the likelihood of a favorable medical response and/or require prolonged treatment, the patient's UTI was considered "complicated." In addition to eight patients with polymicrobic UTIs (usually involving enterococci or Pseudomonas aeruginosa), 48 men (i.e., 51 percent of the total population) had an identifiable complication. Complications included benign prostatic hypertrophy in 13 patients; prostatic cancer in four; urethral stricture in four; quadriplegia/paraplegia with indwelling urinary catheter in four; prostatism in three; and other conditions commonly recognized as altering the response to antibiotic treatment. Among the 95 patients treated, 76 (80 percent) were considered to have had a cure and five (5 percent) showed improvement. Fourteen patients (15 percent) failed to show a response to treatment. Of the 48 patients with UTI and defined complications, 36 (75 percent) had a cure, three (6 percent) showed improvement, and therapy failed in nine (19 percent). Ninety-seven percent (105 of 108) of the pretreatment bacterial isolates were susceptible to norfloxacin. In addition to the three resistant organisms that were present prior to therapy, three organisms (two P. aeruginosa and one Enterobacter) persisted and acquired resistance during therapy. Five adverse clinical experiences and six adverse laboratory experiences were noted. Only one of the former (mild heartburn) was thought to be drug related, and no adverse experience was considered serious or required discontinuation of treatment. Gastrointestinal tolerability of oral norfloxacin was good.
对95名患有非菌血症性尿路感染（UTIs）（清洁中段尿细菌计数大于或等于10⁵菌落形成单位/毫升）且接受诺氟沙星治疗（400毫克口服，每日两次）的男性患者的数据进行了回顾性分析。治疗持续时间从至少需要7天到最长30天不等。如果存在可能降低良好医疗反应可能性和/或需要延长治疗时间的潜在解剖学或功能状况，则患者的UTI被视为“复杂性”。除了8名患有多种微生物UTIs的患者（通常涉及肠球菌或铜绿假单胞菌）外，48名男性（即占总人口的51%）有可识别的并发症。并发症包括13例良性前列腺增生；4例前列腺癌；4例尿道狭窄；4例因留置导尿管导致四肢瘫痪/截瘫；3例前列腺增生；以及其他通常被认为会改变对抗生素治疗反应的状况。在接受治疗的95名患者中，76名（80%）被认为已治愈，5名（5%）有所改善。14名患者（15%）对治疗无反应。在48例患有UTI且有明确并发症的患者中，36例（75%）治愈，3例（6%）有所改善，9例（19%）治疗失败。97%（108株中的105株）治疗前的细菌分离株对诺氟沙星敏感。除了治疗前存在的3株耐药菌外，3株菌（2株铜绿假单胞菌和1株肠杆菌）在治疗期间持续存在并获得耐药性。记录了5次不良临床事件和6次不良实验室事件。前者中只有1次（轻度烧心）被认为与药物有关，且没有不良事件被认为严重或需要停药。口服诺氟沙星的胃肠道耐受性良好。
